Physician profile
Jonathan Koff
NPI 1104926302
$9,179.46
in general payments reported to CMS, 2019-2025
41 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $470 · 2021: $475 · 2022: $1,009 · 2023: $1,756 · 2024: $2,161 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,503 · Education: $42.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,503.04 |
| Education | $42.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $971.68 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $927.43 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $830.42 | 2019-2025 | |
| Celgene Corporation | $771.18 | 2022-2024 | Zeposia |
| Genzyme Corporation | $461.82 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.29 | 2019-2025 | Xifaxan, Plenvu |
| Medtronic, INC. | $429.65 | 2021-2024 | Gi Genius |
| Boston Scientific Corporation | $371.55 | 2023-2025 | Resolution Clip, General - Endochoice, Captivator II |
| Qol Medical, LLC | $233.96 | 2019-2025 | Sucraid, Sucraid |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Intercept Pharmaceuticals, INC. | $189.54 | 2020-2025 | Ocaliva |
| Celltrion USA INC. | $169.42 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $164.28 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $154.07 | 2019-2024 | Rebyota |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $151.21 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $124.30 | 2020-2025 | Injectafer |
| Janssen Scientific Affairs, LLC | $120.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $117.94 | 2021 | |
| Braintree Laboratories, INC. | $76.89 | 2019-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $71.86 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $70.79 | 2025 | Monoferric |
| Phathom Pharmaceuticals, INC. | $66.60 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $59.92 | 2025 | Ibsrela |
| Pentax of America, INC. | $56.71 | 2023 | Video Colonoscope |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.41 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $46.26 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $44.01 | 2019-2024 | Dificid, Zinplava |
| Allergan, INC. | $39.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $39.51 | 2022-2025 | Givlaari |
| Aimmune Therapeutics, INC. | $38.69 | 2025 | Zenpep |
| Endo Pharmaceuticals INC. | $31.33 | 2019-2020 | |
| Echosens North America, INC. | $28.98 | 2023 | Fibroscan |
| Novo Nordisk INC | $27.20 | 2025 | Wegovy |
| Amgen INC. | $23.37 | 2022 | |
| Orphalan INC | $23.04 | 2025 | Cuvrior |
| Sandoz INC. | $21.36 | 2023 | Hyrimoz |
| Madrigal Pharmaceuticals | $18.35 | 2024 | Resmetirom |
| Fresenius Kabi USA, LLC | $15.57 | 2024 | Idacio |
| Integra Lifesciences Corporation | $15.46 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Endogastric Solutions, INC | $15.14 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Koff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.